The report On The Global Gynecology Drug Market offers the latest quick insights on the market trends for users. In addition, the report will help you to understand opportunities in each industry vertical, which is key and allows you to gain competitive advantage and keep up with trends as they occur. The report are valuable to those market seekers;— who would like an evaluation of the global Gynecology drug market, the industry trends and revenue forecasts for the major players in this market
The global gynecology drug market will reach a total value of $12.5 billion by 2025, according to the latest report published by Global Market Insights. The challenge faced by the markets is anticipated to increase year after year as many prescription drugs and treatable gynecological conditions are curable. Many worry that women under 40 seem to be at greater mitigated risk than older women, which also means that marketing techniques may target young millennials more effectively. However, extrapolating from the known figures from market data and the latest government statistics cannot function as a reliable calculation for accurate estimating additional sales, positive
What is a gynecology drug?
Gynecology drug refers to a medication administered in a physician’s office or clinic for the treatment of abnormal vaginal bleeding, abnormal mammograms, problems with ovulation, and prevention of HIV. The market for gynecology drugs is moderately large, but growing at an exponential rate. In terms of share, vaccines for vulvovaginal diseases were the top-selling product in 2016 and covered one third of the total gynecology drug market.
Gynecologist drugs: The market share of different manufacturers
Several of the leading manufacturers in the gynecology drug market are Astellas, J&J, Pfizer, Boehringer Ingelheim, Alembic, Bausch & Lomb and McNeil. A majority of these have a national presence but several have a global presence as well. These top five manufacturers account for almost 58% of that market share. All the major regions covered such as North America, Europe, Asia-Pacific and Latin America tend to dominate the overall gynecologist drugs market share with North America being the largest at 29% followed by Europe at 28%, Asia-Pacific at 15%, Latin America has 2% market share and lastly Africa region stands as a single player with 0.5% market share
The forecast on the gynecology drugs market size to 2025
The global gynecology drug market size is expected to reach USD 6.79 billion by 2025, registering high CAGR at 20.1% during the forecast period, according to GBI Research report, “Gynecology Drugs Industry – Global Market Analysis & Forecast”.
Gynecology drug market is estimated to be worth $364 billion by 2023, with a CAGR of 6.9% over the forecast period of 2014-2023. The US accounted for more than 36% share of this industry in 2017 and China around 21%.